94994-39-5 (5-羟基甲基异噁唑-3-羧酸乙酯,4-{(tert-butoxy)carbonyl(methyl)amino}butanoic acid)

CAS号:
94994-39-5
中文名称:
5-羟基甲基异噁唑-3-羧酸乙酯
英文名称:
4-{(tert-butoxy)carbonyl(methyl)amino}butanoic acid
分子式:
C10H19NO4
分子量:
217.26216340065

5-羟基甲基异噁唑-3-羧酸乙酯(94994-39-5)名称与标识符

名称

中文别名:
4-(叔丁羰基(甲基)氨基)丁酸;5-羟基甲基异噁唑-3-羧酸乙酯;
英文别名:
4-((tert-Butoxycarbonyl)(methyl)amino)butanoic acid;5-Hydroxymethylisoxazole-3-carboxylic acid ethyl ester;4-[(TERT-BUTOXYCARBONYL)(METHYL)AMINO]BUTANOIC ACID;4-[[(1,1-Dimethylethoxy)carbonyl]methylamino]butanoic acid (ACI);4-[(tert-Butoxycarbonyl)(methyl)amino]butyric acid;4-[N-(tert-Butoxycarbonyl)-N-methylamino]butyric acid;4-[N-Methyl-N-(tert-butoxycarbonyl)amino]butyric acid;F8880-8286;AB6481;4-(N-tert-butoxycarbonyl-N-methylamino)butyric acid;EN300-49664;4-((tert-butoxycarbonyl)(methyl)amino)butanoicacid;4-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoic Acid;SY107643;SCHEMBL693386;PXAKQDWAISFHCM-UHFFFAOYSA-N;4-[{[(1,1-Dimethylethyl)oxy]carbonyl}(methyl)amino)butanoic acid;Z382704896;Boc-N-methyl-gamma-aminobutyric acid;4-{[(tert-butoxy)carbonyl](methyl)amino}butanoic acid;94994-39-5;4-(N-t-butyloxycarbonyl-N-methylamino)butanoic acid;CS-W005842;AS-19947;4-(N-BOC-N-METHYL-AMINO)-BUTYRIC ACID;MFCD09831984;4-[(TERT-BUTOXYCARBONYL)(METHYL)AMINO]BUTANOICACID;4-((Boc)(methyl)amino)butanoic acid;4-(tert-butoxycarbonyl-methyl-amino)-butyric acid;4-[{[(1,1-dimethylethyl)oxy]carbonyl}(methyl)amino]butanoic acid;4-([(tert-Butoxy)carbonyl](methyl)amino)butanoic acid;AKOS008126011;

标识符

MDL:
MFCD09831984
InChIKey:
PXAKQDWAISFHCM-UHFFFAOYSA-N
Inchi:
1S/C10H19NO4/c1-10(2,3)15-9(14)11(4)7-5-6-8(12)13/h5-7H2,1-4H3,(H,12,13)
SMILES:
O=C(N(CCCC(O)=O)C)OC(C)(C)C

5-羟基甲基异噁唑-3-羧酸乙酯(94994-39-5)物化性质

实验特性

  • LogP : 1.71810
  • PSA : 66.84000
  • 熔点 : 62-65°C

计算特性

  • 精确分子量 : 217.13100
  • 氢键供体数量 : 1
  • 氢键受体数量 : 5
  • 可旋转化学键数量 : 7
  • 同位素质量 : 217.13140809g/mol
  • 重原子数量 : 15
  • 复杂度 : 232
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 0
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : 1
  • 拓扑分子极性表面积 : 66.8Ų

5-羟基甲基异噁唑-3-羧酸乙酯(94994-39-5)推荐厂家 更多厂家(18)

公司名称手机号/电话联系人QQ微信询单
北京百灵威科技有限公司 18210857532翟先生 3650742139
询单
上海瀚思化工有限公司 18939883912
021-34536277
顾经理 3003949364
询单
上海一基实业有限公司 13311756131
021-60548336 QQ:2355265332 QQ:2851717387
胡经理 2355265332
询单
上海一基实业有限公司 13311756052
021-60526763 13311756052 13311756131
胡经理 2355265332
询单
上海绩祥生物科技有限公司 13093077543陆经理 3985448220
询单
上海腾准生物科技有限公司 19821570922
021-34053661
张经理 3003871136
询单
赫澎(上海)生物科技有限公司 13122891558
186-16545970
张硕 3418426269
询单
金锦乐(湖南)化学有限公司 金锦乐 1226360695
询单
江苏艾康生物医药研发有限公司 18795912720
025-66061636
杨情情 3004779232
询单
南兴化工(江苏)有限公司 18651116180
0512-66387035
闵慧萍 3771156959 询单

5-羟基甲基异噁唑-3-羧酸乙酯(94994-39-5)合成路线

合成路线:1 步
反应条件:
参考文献:
Preparation of substituted quinolinone derivatives for use as muscarinic receptor antagonists and β2 adrenergic receptor agonists
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of carbamate prodrugs for inhibition of inosine monophosphate dehydrogenase (IMPDH)
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Fragment-based domain shuffling approach for the synthesis of pyran-based macrocyclic compounds
Comer, Eamon; Liu, Haibo; Joliton, Adrien; Clabaut, Alexandre; Johnson, Christopher; et al, Proceedings of the National Academy of Sciences of the United States of America, 2011, 108(17), 6751-6756
合成路线:1 步
反应条件:
参考文献:
Antibody drug conjugates comprising STING modulators
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Aminopropyl thiazole derivatives useful as fungicides, and their preparation procedures
, Germany, , ,
合成路线:1 步
反应条件:
参考文献:
Peptoads, a group of amphiphilic long-chain triamides
Menger, Fredric M.; Zhang, Hailing, Langmuir, 2005, 21(23), 10428-10438
合成路线:1 步
反应条件:
参考文献:
Total Synthesis of Cyclosporin on Solid-Phase Support
Gerber, Andreas, 2009, , ,
合成路线:1 步
反应条件:
参考文献:
Design, synthesis, and cyclization of 4-aminobutyric acid derivatives: potential candidates as self-immolative spacers
DeWit, Matthew A.; Gillies, Elizabeth R., Organic & Biomolecular Chemistry, 2011, 9(6), 1846-1854
合成路线:1 步
反应条件:
参考文献:
DC-SiGN antibody conjugates comprising STING receptor agonists and their use in cancer therapy
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Antibody conjugates comprising sting agonist
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of chemokine receptor binding (benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amines and related heterocyclic compounds with enhanced efficacy against AIDS and other disorders
, United States, , ,
合成路线:1 步
反应条件:
参考文献:
Lipid compound for cell transfection, and liposome and pharmaceutical composition comprising the same for treating genetic abnormality-induced disease
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Synthesis and evaluation of xanomeline analogs-Probing the wash-resistant phenomenon at the M1 muscarinic acetylcholine receptor
Kane, Brian E.; Grant, Marianne K. O.; El-Fakahany, Esam E.; Ferguson, David M., Bioorganic & Medicinal Chemistry, 2008, 16(3), 1376-1392
合成路线:1 步
反应条件:
参考文献:
Preparation of 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as β-lactamase inhibitors
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
(R)-N-ethyl-5-fluoro-N-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Synthesis of Pyridazines or 1,2,4-Triazines containing spirocyclic amines treating cancers and diabetes
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of substituted spiro derivatives, especially, (R)-N-ethyl-5-fluoro-N-isopropyl-2-[[5-[2-[6-[(2-methoxyethyl)(methyl)amino]-2-methylhexan-3-yl]-2,6-diazaspiro[3.4]octan-6-yl]-1,2,4-triazin-6-yl]oxy]benzami de and its dibesylate as inhibitors of menin-MLL interaction and their use in combination with a BCl-2 inhibitor and optionally one other antitumor agents
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Combination therapies
, World Intellectual Property Organization, , ,